Top Markets
Coin of the day
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI
Classificação em ações #31758
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Preço da ação
$1.10
Última sincronização: 2026-08-17
Valor de mercado
$12.14M
Variação (1 dia)
11.11%
Variação (1 ano)
77.42%
País
US
Negociar Brainstorm Cell Therapeutics Inc. (BCLI)

Categoria

EPS de Brainstorm Cell Therapeutics Inc. (BCLI)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Brainstorm Cell Therapeutics Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Brainstorm Cell Therapeutics Inc. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
- -
KR